Activity Provided By:

The University of Texas MD Anderson Cancer Center

A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL

Overview / Abstract:	Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL.
Expiration	Jan 31, 2024
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Online, Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	ACCME
Presenters / Authors / Faculty	Chair Nitin Jain, MD Associate Professor Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, TX Co-Chair Jacqueline Barrientos, MD, MS Chief, Hematologic Malignancies Director, Oncology Research Assistant Professor Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Adjunct Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell Adjunct Associate Professor, Feinstein Institutes for Medical Research Mount Sinai Medical Center Miami Beach, FL Faculty Catherine Coombs, MD Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, CA Sameer Parikh, MD, MBBS (Presenter) Assistant Professor of Medicine Department of Medicine, Division of Hematology Mayo Clinic Rochester, MN
Sponsors / Supporters / Grant Providers	Sponsored by the University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL) Supported by an educational grant from Lilly.
Keywords / Search Terms	ACHL BTK inhibitors, CLL/SLL, hematology, oncology, targeted agents, chronic lymphocytic leukemia, small lymphocytic lymphoma, Bruton’s tyrosine kinase (BTK) inhibitors, relapsed, refractory, The University of Texas MD Anderson Cancer Center, Sameer Parikh, MD, targeted therapies, clinical trial data, treatment plans Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map